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Abstract: Pegaptanib sodium (Macugen®) blocks the extracellular vascular endothelial growth 
factor (VEGF) isoform VEGF165, whose elevated levels are associated with the development 
of choroidal neovascularization (CNV). This selective inhibition prevents binding to the 
VEGF receptors and the development of the increased vascular permeability and the CNV 
associated with neovascular age-related degeneration (AMD). The VEGF Inhibition Study 
In Ocular Neovascularization (VISION) demonstrated that pegaptanib sodium confers clini-
cally meaningful beneﬁ  t in the treatment of all angiographic subtypes of neovascular AMD. It 
also has a favorable safety proﬁ  le after 1 and 2 years of continuous treatment, and recent data 
suggest that the agent has a disease-modifying effect. Post hoc analysis of VISION suggests 
that treatment beneﬁ  t may be greatest in patients with early lesions, in whom 80% achieved 
the primary endpoint of  15 letters lost, 47% maintained visual acuity (VA), and 20% gained 
 15 letters of vision. Similarly, our own clinical experience indicates that pegaptanib sodium 
achieves better outcomes in early lesions than in established lesions, particularly in patients 
with previously untreated minimally classic and occult lesions in whom VA improvement and 
lesion size stabilization has been recorded. Observations indicate that pegaptanib sodium has a 
slower mode of action than unselective VEGF inhibitors, resulting in an average of 3–4 injec-
tions being required to stabilize VA and lesion size. Pegaptanib sodium has good efﬁ  cacy and 
safety proﬁ  les and represents a good treatment option for patients with early CNV membranes 
associated with neovascular AMD.
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Vascular endothelial growth factor (VEGF) is a proangiogenic factor that plays a key 
role in the pathogenesis of neovascular age-related macular dengeneration (AMD). 
Elevated levels of the VEGF165 isoform lead to the development of choroidal neovas-
cularization (CNV), the growth of fragile, new vessels in the macula that may cause 
exudation, and hemorrhages. Pegaptanib sodium (Macugen®, [OSI] Eyetech Phar-
maceuticals, Pﬁ  zer) blocks the extracellular VEGF165 isoform and inhibits its binding 
to the VEGF receptors. This action prevents the increased vascular permeability and 
choroidal neovascularization that is associated with neovascular AMD.
Efﬁ  cacy
The results of the VEGF Inhibition Study In Ocular Neovascularization (VISION) 
have shown that pegaptanib sodium confers statistically signiﬁ  cant, and clinically 
meaningful, beneﬁ  t in the treatment of all angiographic subtypes of neovascular 
AMD (Gragoudas et al 2004; Gonzales 2005). The trials randomized patients to 
receive pegaptanib sodium 0.3 mg, 1.0 mg, or 3.0 mg intravitreal (ITV) injections or 
sham injections every 6 weeks. The primary end point was the proportion of patients 
losing fewer than 15 letters from baseline visual acuity (VA) at 54 weeks. This was 
achieved in 70% of patients receiving 0.3 mg pegaptanib sodium, regardless of Clinical Ophthalmology 2008:2(3) 486
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photodynamic therapy (PDT), compared with 55% in the 
placebo patient group (p   0.001). No additional beneﬁ  ts, in 
terms of clinical efﬁ  cacy or safety, were measured in the 1.0 
mg and 3.0 mg patient groups compared with those receiving 
the lower 0.3 mg dose.
During the second year of the study, mean VA was 
stabilized in patients receiving 0.3 mg pegaptanib sodium, 
while those receiving placebo injections experienced con-
tinued vision loss. At year 2, change in vision (recorded as 
letters observed) was approximately 50% better in patients 
receiving 0.3 mg pegaptanib sodium than in those receiving 
placebo injections, irrespective of CNV lesion subtype 
(Chakravarthy et al 2006).
On the basis of these ﬁ  ndings, pegaptanib sodium has 
been approved at a recommended dosage of 0.3 mg, admin-
istered as an ITV injection every 6 weeks, for the treatment 
of neovascular AMD.
The results of VISION appear less encouraging 
than those recorded in the early ranibizumab clinical 
trials – the ANti-VEGF antibody for the treatment of 
predominantly classic CHORoidal neovascularization 
in AMD (ANCHOR) trial and the Minimally classic/oc-
cult trial of the Anti-VEGF antibody Ranibizumab In 
the treatment of Neovascular AMD (MARINA) (Brown 
et al 2006; Rosenfeld et al 2006a, b). However, it is im-
portant to consider differences in the patient populations 
recruited for the studies: MARINA recruited patients 
with minimally classic or occult lesions with no classic 
CNV, and ANCHOR recruited patients with predomi-
nantly classic CNV lesions. VISION, however, enrolled 
patients with all neovascular AMD lesion subtypes (25% 
predominantly classic, 39% occult with no classic and 
36% minimally classic).
Safety
Pegaptanib sodium has a favorable safety proﬁ  le after 1 
and 2 years of continuous treatment. The 2-year safety 
results demonstrated that all doses of pegaptanib were well 
tolerated et al (D’Amico et al 2006). The most common ocular 
adverse events were transient, mild to moderate in intensity, 
and attributed to the injection preparation and procedure. 
In year 1, serious injection-related complications included 
endophthalmitis (at a rate of 0.16% per injection). Most of 
the cases resulted from violations of the injection preparation 
protocol and the rate dropped to 0.07% in the second year after 
reinforced aseptic procedure. In general, systemic adverse 
events were relatively low and similar in the pegaptanib 
sodium and placebo patient groups (D’Amico et al 2006).
Retrospective analysis
Mills et al (2007) determined that the treatment beneﬁ  ts af-
forded by pegaptanib sodium are due to its disease modifying 
effect, an analysis of which has been proposed by Whitehouse 
et al (1998) and by McDermott et al (2002). The authors of 
the aforementioned papers analyzed data from the second 
year of VISION. After the initial 54-week treatment period, 
patients were re-randomized to either continue or discontinue 
treatment (in an unmasked fashion) for a further 48 weeks. 
The authors found that visual outcomes in patients who were 
randomized to discontinue treatment after 54 weeks and who 
were followed for a further 48 weeks, were signiﬁ  cantly 
different to those in patients receiving placebo injections in 
terms of loss of 15 letters of vision (relative risk [RR] 0.70, 
95% conﬁ  dence interval [CI] 0.57–0.88; p = 0.002), indicat-
ing that the treatment had a modifying effect on the disease 
(Mills et al 2007).
In the post hoc analysis of VISION, the treatment beneﬁ  t 
seen in patients receiving 0.3 mg pegaptanib sodium was 
particularly marked in those with early lesions; 80% of 
those with early lesions achieved the primary end point of 
 15 letters lost. In addition, nearly half (47%) of patients 
with early lesions maintained VA when treated with 0.3 mg 
pegaptanib sodium, and 20% of these patients gained  15 
letters of vision (Gonzales 2005).
Clinical practice
In our clinical centre, we treated 45 eyes (in 45 patients) 
with pegaptanib sodium, between June 2006 and June 2007. 
The lesion subtypes treated were: classic lesions in 5 eyes, 
minimally classic lesions in 7 eyes, and occult lesions in 
33 eyes. Of these patients, 22 were followed for 18 weeks.
From our own clinical experience of treating all neo-
vascular AMD lesion subtypes with pegaptanib sodium, 
the efﬁ  cacy of the agent differs when comparing treatment 
outcomes in patients with early lesions and those with estab-
lished lesions. In our department it has been observed that 
pegaptanib sodium treatment in early lesions results in better 
outcomes than in established lesions. This is particularly true 
in patients with previously untreated minimally classic and 
occult lesions in whom VA improvement and lesion size sta-
bilization has been recorded. These results are very important 
and contrast with the relatively moderate treatment effects 
seen in minimally classic and occult lesion after PDT.
In our patients, a frequent discrepancy was also observed 
between anatomic factors, examined with ﬂ  uorescein angiog-
raphy (FAG) and indocyanine green angiography (ICGA), and 
functional factors: VA improvement is often not correlated Clinical Ophthalmology 2008:2(3) 487
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with lesion size changes in FAG+ICGA. Our observations 
have also led us to conclude that pegaptanib sodium has a 
slower mode of action compared with that of unselective 
VEGF inhibitors. Clinical experience would suggest that, 
because pegaptanib sodium’s mode of action is slower, at least 
3 ITV injections are required to produce good efﬁ  cacy.
In a recent study, Quiran et al evaluated the efﬁ  cacy of 
pegaptanib sodium as primary therapy in 90 patients with 
naive lesions (80% occult, 13% minimally classic, and 7% 
predominantly classic) (Quiran et al 2007). All patients were 
injected with 0.3 mg of ITV pegaptanib sodium at 6-week 
intervals. FAG and OCT were carried out at baseline and 
were repeated after 3 treatments, whereafter an additional 
ITV injection of pegaptanib sodium was administered if the 
CNV was observed to be active. A response rate of 90% was 
recorded with: 20% of patients gaining  3 lines of vision; 
vision stabilization being achieved in 70% of patients, and 
a loss of  3 lines being recorded in 10% of patients. An 
average of 3.5 injections were administered in those patients 
who experienced a gain in vision of  3 lines.
Our experience echoes the ﬁ  ndings of Quiran et al in that 
we also found 3–4 injections to be enough to stabilize the le-
sion size and to either stabilize or improve VA in the majority 
of patients with early lesions. One occult lesion treated with 
pegaptanib sodium is described in the following case study.
An 82-year-old woman was referred to our department 
after a loss of VA in her right eye (RE). Best corrected VA 
(BCVA) was 10/20 in her RE and 18/20 in her left eye. 
Biomiscropy of the anterior segment was unremarkable in 
both eyes. FAG+ICGA and OCT revealed an occult CNV 
membrane associated with neovascular AMD in the RE (see 
Figure 1). The patient was treated with 5 ITV injections of 
of pegaptanib sodium given 6-weekly.
FAG+ICGA and OCT were performed before every 
injection. The patient’s RE VA stabilized after 2 injec-
tions and FA+ICGA showed an increase in lesion leakage. 
At follow-up after the third injection, VA in the RE had 
improved (16/20) and the lesion size was stable (as as-
sessed with either with FAG+ICGA and OCT). One month 
after the ﬁ  fth ITV injection, both VA and lesion size were 
stable and treatment was stopped. At follow-up 9 months 
after last injection, BCVA was 16/20 and FAG+ICGA and 
OCT showed an absence of lesion activity (see Figure 1).
Stable VA is commonly seen after initial injections with 
selective anti-VEGF treatment, but lesion activity often per-
sists on angiography. As the above clinical case exempliﬁ  es, 
however, VA and the angiographic pattern in the discussed 
patient were stable after only 2 injections of pegaptanib 
sodium and the beneﬁ  cial effects of treatment were evident 
after only 3 treatments.
From our clinical experience, we conclude that at this 
time pegaptanib sodium has good efﬁ  cacy and safety proﬁ  les 
and represents a good treatment option for patients with early 
CNV membranes associated with neovascular AMD.
Figure 1 Fluorescein angiography (FAG) and indocyanine green angiography (ICGA) from an 82-year-old female patient after loss of visual acuity (VA) in her right eye (RE) 
and who received 5 injections of intravitreal (ITV) pegaptanib sodium.
a. pre-injection; b. post second injection; c. post third injection; d. 9 months post ﬁ  fth injection.Clinical Ophthalmology 2008:2(3) 488
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